Venlafaxine: Loss of Antidepressant Effect and Its Management
J Clin Psychiatry 1998;59(7):381-382 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Sir: The antidepressant profile of venlafaxine includes a broad range of clinical activity, as its effect is not influenced by factors such as the presence of melancholic features, age, gender, severity, or duration of depression. A recent analysis of the treatments of major depression revealed that venlafaxine had the highest efficacy rates and lowest dropout rates when compared with tricyclics and serotonin reuptake inhibitors. Up to one third of patients with rigorously defined treatmentresistant depression show a favorable response to venlafaxine, but nearly half of these patients are unable to sustain the antidepressant effect during the first 3 months of treatment.